Clinical Trials Logo

Receptor, ErbB-2 clinical trials

View clinical trials related to Receptor, ErbB-2.

Filter by:
  • None
  • Page 1

NCT ID: NCT05145179 Not yet recruiting - Receptor, ErbB-2 Clinical Trials

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

Start date: December 1, 2021
Phase: Phase 1
Study type: Interventional

The study will consist of two parts: a dose-escalation part (Part 1) and a dose expansion part (Part 2). In both study parts, SSGJ-705 will be administered,the administration duration may be adjusted based on outcomes of previous patients if necessary) followed by safety, PK, PD, potential anti tumor effects and immunogenicity evaluation.

NCT ID: NCT03331601 Recruiting - Carcinoma Clinical Trials

Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients

Start date: October 16, 2017
Phase: Phase 2
Study type: Interventional

This study investigates the uptake of the radiopharmaceutical 68-GaNOTA-Anti-HER2 VHH1 in brain metastasis using PET/CT imaging. Patients with HER2-positive and HER2-negative cancer will be included and the uptake in their lesions will be compared. Optional 68-GaNOTA-Anti-HER2 VHH1 scans may be performed during or after treatment, at time points 12±6 weeks and 24±9 weeks after the first scan.